Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01508195 · ClinicalTrials.gov registry record · Phase 1
A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT01508195 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 64 participants.
The verdict
NCT01508195, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the bioequivalence of fixed dose combination (FDC) tablets of canagliflozin and metformin immediate release (IR) in comparison with the individual components of the FDC tablets (canagliflozin and metformin IR).
Interventions
- DRUG Canagliflozin tablets
- DRUG Metformin IR tablets
- DRUG Canagliflozin/metformin IR FDC tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01508195
The ClinicalTrials.gov registry entry for NCT01508195 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Canagliflozin tablets is the first listed.
NCT01508195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01508195 about?
NCT01508195 is a clinical study titled "A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers". The purpose of this study is to evaluate the bioequivalence of fixed dose combination (FDC) tablets of canagliflozin and metformin immediate release (IR) in comparison with the individual components of the FDC tablets (canagliflozin and metformin IR).
What is the current status of trial NCT01508195?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2012-01. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01508195?
The interventions under investigation include: Canagliflozin tablets (DRUG), Metformin IR tablets (DRUG), Canagliflozin/metformin IR FDC tablets (DRUG).
Who is sponsoring clinical trial NCT01508195?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.